stoxline Quote Chart Rank Option Currency Glossary
Exact Sciences Corporation (EXAS)
71.34  -1.61 (-2.21%)    04-12 16:00
Open: 72.92
High: 73.095
Volume: 2,342,187
Pre. Close: 72.95
Low: 70.79
Market Cap: 12,950(M)
Technical analysis
2024-04-12 4:49:09 PM
Short term     
Mid term     
Targets 6-month :  92.99 1-year :  108.61
Resists First :  79.62 Second :  92.99
Pivot price 69.85
Supports First :  65.93 Second :  57.47
MAs MA(5) :  72.69 MA(20) :  67.55
MA(100) :  65.4 MA(250) :  73.18
MACD MACD :  3 Signal :  2.7
%K %D K(14,3) :  63.9 D(3) :  67.3
RSI RSI(14): 60.5
52-week High :  100.76 Low :  56.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EXAS ] has closed below upper band by 39.9%. Bollinger Bands are 50.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 73.25 - 73.69 73.69 - 74.02
Low: 69.75 - 70.33 70.33 - 70.76
Close: 70.58 - 71.43 71.43 - 72.07
Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Headline News

Sat, 13 Apr 2024
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Nisa Investment Advisors LLC - Defense World

Sat, 13 Apr 2024
Exact Sciences (NASDAQ:EXAS) Shares Gap Down to $73.60 - Defense World

Thu, 11 Apr 2024
Exact Sciences announces debt exchange transaction (NASDAQ:EXAS) - Seeking Alpha

Thu, 11 Apr 2024
Exact Sciences issues $620.7 million in new convertible notes -

Thu, 11 Apr 2024
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes - Yahoo Finance

Wed, 10 Apr 2024
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Diagnostics & Research
Shares Out 0 (M)
Shares Float 182 (M)
Held by Insiders 1.7956e+008 (%)
Held by Institutions 1 (%)
Shares Short 7,270 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.0223e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -0.9 %
Operating Margin -8.2 %
Return on Assets (ttm) -12 %
Return on Equity (ttm) -3.1 %
Qtrly Rev. Growth 2.5e+009 %
Gross Profit (p.s.) 13.82
Sales Per Share -5.37
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 156 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 170.5
Price to Book value 0
Price to Sales -13.3
Price to Cash Flow 5.06
Stock Dividends
Dividend 0
Forward Dividend 6.52e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android